Our team can help you assess if the patient profiles most common in your practice support having UroVal® BRS in your office. UroVal® BRS is commonly used in practices that provide pelvic floor rehabilitation, manage patients with urinary incontinence, or care for patients who may progress to advanced therapies such as sacral or tibial neuromodulation.

UroVal® allows you to objectively measure a reflex that is not directly assessed by urodynamics or other standard testing, providing a more complete picture of sacral nerve function. Manual reflex testing, including the anal wink, is observational and may not be precise enough to establish the integrity of the sacral nerves. UroVal® measures bulbocavernosus reflex latency, allowing confirmation of whether the reflex is present even when it appears diminished or absent on manual exam. This provides more precise, reproducible information about sacral nerve function to complement your physical exam and symptom assessment.

There are no formal contraindications for the UroVal® BRS assessment. The test is noninvasive and does not use electrical stimulation. As with any clinical assessment, providers should use standard clinical judgment and consider patient comfort and safety when determining whether to perform the test.

Bulbocavernosus reflex latency reflects the time required for a neural signal to travel through the S2–S4 reflex pathway. Prolonged latency indicates delayed conduction within this pathway compared to expected values. This finding suggests altered sacral reflex function but does not, on its own, define symptom severity or predict clinical outcomes.

Latency values should be interpreted in the context of the patient’s symptoms, exam findings, and overall clinical picture.

Many providers use this as part of their assessment for patients after being diagnosed with urinary or fecal incontinence or other sacral nerve dysfunction to establish a baseline. This objective assessment can be documented and referenced over time to track patient progress. It can also support clinical documentation when patients are not responding to conservative therapies and require progression to the next step in care.

UroVal® helps characterize whether sacral nerve dysfunction may be contributing to a patient’s symptoms. When neurologic involvement is suspected, therapies that primarily act on muscle or end-organ activity may have different clinical considerations than treatments that address neural pathways. UroVal® adds objective physiologic information that can be referenced during shared decision making. It does not replace established treatment algorithms or predict response to individual therapies.

Manual reflex testing, including the anal wink, is observational and limited to assessing whether a response appears present or absent. These exams do not quantify reflex timing or provide information about sacral nerve pathway integrity. In addition, patient positioning, examiner techniques, and subtle responses can make findings difficult to interpret consistently. UroVal® provides an objective, reproducible measurement of bulbocavernosus reflex latency to complement the physical exam. In addition, the manual exam is not reimbursed by insurance.

The national 2026 average Medicare allowable for the UroVal® BRS assessment is $255.22. Actual reimbursement will vary by state and region.

It cannot be billed or performed on the same day as urodynamics.

Payors may reimburse for up to three assessments per year depending on the insurance carrier. Subject to payor policy for additional testing, prior authorization may be required.

The UroVal® BRS assessment can typically be completed within 5 minutes once the patient is undressed. A cart is provided to transition the device from room to room. Many offices perform the assessment during the patient’s visit once indicated. Others schedule patients separately and dedicate a room for testing.